Anti-CD20 antibody treatment of non-Hodgkin lymphomas

被引：19
|
作者：
Engelhard, Marianne [1 ]
机构：
[1] Univ Hosp, Dept Radiotherapy, D-45122 Essen, Germany
来源：
CLINICAL IMMUNOLOGY | 2016年 / 172卷
关键词：
Non-Hodgkin lymphoma; Immunotherapy; CD20; antigen; Anti-CD20; antibody; Rituximab; CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL LYMPHOMA; RANDOMIZED CONTROLLED-TRIAL; ADVANCED FOLLICULAR LYMPHOMA; CHEMOTHERAPY PLUS RITUXIMAB; CHOP-LIKE CHEMOTHERAPY; REFRACTORY LOW-GRADE; MONOCLONAL-ANTIBODY; OPEN-LABEL; EARLY-STAGE;
D O I：
10.1016/j.clim.2016.08.011
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The CD20 antigen characteristic for mature B-cell is also expressed on B-cell Non-Hodgkin lymphomas (NHL). It thus presents a possible target for immunotherapy. NHL respond readily to radio- and/or chemotherapy but this standard treatment bears a high risk of relapse. The specific monoclonal anti-CD20-antibody Rituximab, the first to be approved for clinical use, could be shown to improve response rates, response duration, and survival in NHL when combined with standard therapy. This review details the development, clinical application, and future perspectives of anti-CD20-antibody treatment of NHL, thereby proving the efficiency of immunotherapy via targeting of a tumor associated antigen. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码：101 / 104
页数：4
相关论文
共 50 条
  • [1] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Gui, Lin
    Han, Xiaohong
    He, Xiaohui
    Song, Yuanyuan
    Yao, Jiarui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Shuxiang
    Zhang, Weijing
    Gai, Wenlin
    Xie, Liangzhi
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) : 197 - 208
  • [2] A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas
    Feugier, Pierre
    FUTURE ONCOLOGY, 2015, 11 (09) : 1327 - 1342
  • [3] Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma
    Zhang, Haifeng
    Song, Liping
    Ye, Hongtu
    Hu, Lide
    Liang, Wenlu
    Liu, Datao
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2013, 32 (03) : 645 - 654
  • [4] Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
    Sharkey, Robert M.
    Karacay, Habibe
    Johnson, Christine R.
    Litwin, Samuel
    Rossi, Edmund A.
    McBride, Williarn J.
    Chang, Chien-Hsing
    Goldenbero, David M.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (03) : 444 - 453
  • [5] Anti-CD20 Antibody Therapy for B-Cell Lymphomas
    Maloney, David G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (21): : 2008 - 2016
  • [6] Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
    Krasniqi, Ahmet
    D'Huyvetter, Matthias
    Xavier, Catarina
    Van der Jeught, Kevin
    Muyldermans, Serge
    Van der Heyden, Jose
    Lahoutte, Tony
    Tavernier, Jan
    Devoogdt, Nick
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (12) : 2828 - 2839
  • [7] The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
    Christian, Beth A.
    Poi, Ming
    Jones, Jeffrey A.
    Porcu, Pierluigi
    Maddocks, Kami
    Flynn, Joseph M.
    Benson, Don M.
    Phelps, Mitch A.
    Wei, Lai
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 701 - 710
  • [8] Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab
    Schmitz, K
    Brugger, W
    Weiss, B
    Kaiserling, E
    Kanz, L
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 571 - 572
  • [9] Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma
    Negrea, George O.
    Elstrom, Rebecca
    Allen, Steven L.
    Rai, Kanti R.
    Abbasi, Rashid M.
    Farber, Charles M.
    Teoh, Nick
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (04): : 567 - 573
  • [10] Anti-CD20 monoclonal antibodies: reviewing a revolution
    Casan, J. M. L.
    Wong, J.
    Northcott, M. J.
    Opat, S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (12) : 2820 - 2841
12345